Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre

Journal of Substance Abuse Treatment

Volumn 43, Issue 4, 2012, Pages 440-445

  Islam, M Mofizul ^a,b   Topp, Libby ^c   Conigrave, Katherine M ^b,d,e   White, Ann ^f   Reid, Sharon E ^f,g   Grummett, Sara ^f   Haber, Paul S ^b,d   Day, Carolyn A ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f Redfern Harm Minimisation Clinic   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

HCV treatment; Hepatitis C; Injecting drug users; Needle syringe program; Primary healthcare

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C ANTIBODY; METHAMPHETAMINE; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENOTYPE; HEALTH CENTER; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; MALE; MEDICAL AUDIT; NEEDLE SYRINGE PROGRAM; PATIENT REFERRAL; PREVENTIVE HEALTH SERVICE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DELIVERY OF HEALTH CARE, INTEGRATED; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MIDDLE AGED; NEEDLE-EXCHANGE PROGRAMS; PATIENT ACCEPTANCE OF HEALTH CARE; PRIMARY HEALTH CARE; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84868151001     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2012.07.007     Document Type: Article

References (23)

1. Arora S., Thornton K., Murata G., Deming P., Kalishman S., Dion D., et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. New England Journal of Medicine 2011, 364:2199-2207.
2. Bangsberg D.R., Moss A. When should we delay highly active antiretroviral therapy?. Journal of General Internal Medicine 1999, 14:446-448.
3. Davis G.L., Rodrigue J.R. Treatment of chronic hepatitis C in active drug users. New England Journal of Medicine 2001, 345:215-217.
4. Day C., Ross J., Dolan K. Hepatitis C-related discrimination among heroin users in Sydney: Drug user or hepatitis C discrimination?. Drug and Alcohol Review 2003, 22:317-321.
5. Day C.A., Islam M.M., White A., Reid S.E., Hayes S., Haber P.S. Development of a nurse-led primary healthcare service for injecting drug users in inner-city Sydney. Australian Journal of Primary Health 2011, 17:10-15.
6. Day C.A., White B., Thein H.H., Doab A., Dore G.J., Bates A., et al. Experience of hepatitis C testing among injecting drug users in Sydney, Australia. AIDS Care 2008, 20:116-123.
7. Dore G.J. Enhancing hepatitis C treatment uptake and outcomes for injection drug users. Hepatology 2007, 45:3-5.
8. Dore G.J., Law M., MacDonald M., Kaldor J.M. Epidemiology of hepatitis C virus infection in Australia. Journal of Clinical Virology 2003, 26:171-184.
9. Grebely J., Conway B., Raffa J.D., Lai C., Krajden M., Tyndall M.W. Hepatitis C virus reinfection in injection drug users. Hepatology 2006, 44:1139-1145.
10. Grebely J., Genoway K.A., Raffa J.D., Dhadwal G., Rajan T., Showler G., et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence 2008, 93:141-147.
11. Grebely J., Raffa J.D., Lai C., Krajden M., Kerr T., Fischer B., et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. Journal of Viral Hepatitis 2009, 16:352-358.
12. Islam M.M. Needle syringe program-based primary health care centers: Advantages and disadvantages. Journal of Primary Care & Community Health 2010, 1:100-103.
13. Islam M.M., Reid S.E., White A., Grummett S., Conigrave K.M., Haber P.S. Opportunistic and continuing health care for injecting drug users from a nurse-run needle syringe program-based primary health-care clinic. Drug and Alcohol Review 2012, 31:114-115. [author reply 116-117].
14. Islam M.M., Topp L., Day C.A., Dawson A., Conigrave K.M. The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: a narrative synthesis of literature. International Jouranl of Drug Policy 2012, 23:94-102.
15. Iversen J., Topp L., Maher L. Australian NSP survey national data report 1995-2010 2011, The Kirby Institute, UNSW, Sydney, Accessed in September 2011. http://www.med.unsw.edu.au/NCHECRweb.nsf/resources/NSP_Complete2/$file/ANSPS.1995_2010-rev.pdf.
16. Lindenburg C.E., Lambers F.A., Urbanus A.T., Schinkel J., Jansen P.L., Krol A., et al. Hepatitis C testing and treatment among active drug users in Amsterdam: Results from the DUTCH-C project. European Journal of Gastroenterology and Hepatology 2011, 23:23-31.
17. Mauss S., Berger F., Goelz J., Jacob B., Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004, 40:120-124.
18. Mehta S.H., Genberg B.L., Astemborski J., Kavasery R., Kirk G.D., Vlahov D., et al. Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health 2008, 33:126-133.
19. Merrill J.O., Rhodes L.A., Deyo R.A., Marlatt G.A., Bradley K.A. Mutual mistrust in the medical care of drug users: the keys to the "narc" cabinet. Journal of General Internal Medicine 2002, 17:327-333.
20. Razali K., Thein H.H., Bell J., Cooper-Stanbury M., Dolan K., Dore G., et al. Modelling the hepatitis C virus epidemic in Australia. Drug and Alcohol Dependence 2007, 91:228-235.
21. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases 2005, 5:558-567.
22. Stoove M.A., Gifford S.M., Dore G.J. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug and Alcohol Dependence 2005, 77:81-86.
23. Van Thiel D.H., Anantharaju A., Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. American Journal of Gastroenterology 2003, 98:2281-2288.